Detected ·
VALANX Biotech
——
VALANX Biotech raised €3 million to advance its lead antibody-drug conjugate (ADC) program for metastatic triple-negative breast cancer, with candidate selection planned for June 2026.
- Website
- valanx.bio
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-03-12 20:01:37 UTC
- Signal ID
- b44c8bb3-f4de-409b-b4ec-852ec94f0432
As the API returns it
{
"id": "b44c8bb3-f4de-409b-b4ec-852ec94f0432",
"created_at": "2026-03-12T20:01:37.425960Z",
"company_name": "VALANX Biotech",
"company_website_url": "valanx.bio",
"company_linkedin_url": "https://www.linkedin.com/company/valanxbiotech",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*VALANX Biotech raised €3 million to advance its lead antibody-drug conjugate (ADC) program for metastatic triple-negative breast cancer, with candidate selection planned for June 2026.*"
}